MONMOUTH JUNCTION, N.J.,
Feb. 24, 2017 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader using blood purification to treat deadly
inflammation in critically-ill and cardiac surgery patients around
the world, will report fiscal 2016 financial results on
Friday, March 3, 2017 at 11:00AM EST.
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q4 2016 and fiscal year ending
December 31, 2016 followed by a
question and answer session.
Conference Call Details:
Date: Friday, March 3,
2017
Time: 11:00 AM Eastern
Participant Dial-In: 1-719-325-2149
Live Presentation Webcast:
http://public.viavid.com/index.php?id=123053
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed link:
http://public.viavid.com/index.php?id=123053
An archived recording and written transcript of the conference
call will be available under the Investor Relations section of the
Company's website at
http://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 42 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a
multi-center, randomized controlled study that has demonstrated the
safety of intra-operative CytoSorb® use in a heart-lung machine
during complex cardiac surgery. In 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 20,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $18
million from DARPA, the U.S. Army, the U.S. Department of
Health and Human Services, the National Institutes of Health (NIH),
National Heart, Lung, and Blood Institute (NHLBI), U.S. Special
Operations Command (SOCOM) and others. The Company has numerous
products under development based upon this unique blood
purification technology, protected by 31 issued U.S. patents and
multiple applications pending, including CytoSorb-XL, HemoDefend™,
VetResQ™, ContrastSorb, DrugSorb, and others. For more
information, please visit the Company's websites
at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release
includes forward-looking statements intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, statements about our plans,
objectives, representations and contentions and are not historical
facts and typically are identified by use of terms such as "may,"
"should," "could," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential," "continue" and similar words,
although some forward-looking statements are expressed differently.
You should be aware that the forward-looking statements in this
press release represent management's current judgment and
expectations, but our actual results, events and performance could
differ materially from those in the forward-looking statements.
Factors which could cause or contribute to such differences
include, but are not limited to, the risks discussed in our Annual
Report on Form 10-K, filed with the SEC on March 9, 2016, as
updated by the risks reported in our Quarterly Reports on Form
10-Q, and in the press releases and other communications to
shareholders issued by us from time to time which attempt to advise
interested parties of the risks and factors which may affect our
business. We caution you not to place undue reliance upon any such
forward-looking statements. We undertake no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, other than
as required under the Federal securities laws.
Please Click to Follow Us on Facebook and
Twitter
CytoSorbents Contact:
Amy Vogel
Investor Relations
(732) 329-8885 ext. *394
avogel@cytosorbents.com
Public Relations Contact:
Amy Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-report-fiscal-2016-operating-and-financial-results-300412840.html
SOURCE CytoSorbents Corporation